Note to Authors
In this issue
mAbs
Volume 2, Issue 2March/April 2010
View current issue
About the cover
The cover image depicts an antibody engineered for enhanced complement- and cell-mediated effector functions. Designed modifications in the Fc region that...Continue reading
About the Journal
mAbs accepted for inclusion for Medline 11.6.09
In January of 2009 mAbs, the first international peer-reviewed journal of its kind to focus exclusively on monoclonal antibodies, was launched. We believe that this is an excellent time to start the journal because of the increasing focus on mAbs as therapeutics. There has been a rapid increase in mAb R&D by academia, government and industry located world wide. Novel mAb therapeutics are entering clinical study by commercial sponsors at a record pace (Figure 1) that is predicted to continue well into the future. MAbs have proven successful in the clinic (Table 1). In addition, a global market has emerged for the products - several novel mAbs not yet available in the US or EU are now approved in China.
HINARI
Landes Bioscience gladly participates in the World Health Organizations' Access to Research Initiative (HINARI) to provide free online access to all papers published in mAbs to scientists in developing countries worldwide.
Editor-in-Chief
Janice M. Reichert, Ph.D.
Email the Managing Editor.
Online ISSN: 1942-0870 DOI: 10.4161/mabs
Most Popular Downloads
Gregory L. Moore, Hsing Chen, Sher Karki, et al.
Jutta Steigerwald, Tobias Raum, Stefan Pflanz, et al.
Philip W. Hammond
Jody D. Berry, Kevin Hay, James M. Rini, et al.
Chengbin Wu, Hua Ying, Sahana Bose, et al.
Meetings of interest
Keystone Symposia: New Paradigms in Cancer Therapeutics
March 23–28, 2010, Victoria, British Columbia, Canada
Comparability for Biologics
April 12–13, 2010, London, UK
BioTrinity 2010
April 12–14, 2010, Newbury, UK
15th International Human Antibodies &
Hybridomas Conference
April 14–16, 2010, Porto, Portugal
Links of Interest
